Eduardo Vela Nava

1 Introduction Acute coronary syndrome (ACS) is a diverse and complicated medical condition that remains a leading cause of morbidity and mortality worldwide (Ma et al., 2020; Bergmark et al., 2022), despite the provision of optimal medical care. Studies (Sinha et al., 2016; Younis et al., 2016) have shown that over half of ACS patients suffer from metabolic complications, leading to an increased cardiovascular death rate and long-term adverse events.

hospital pharmacy Volume 57  Number 5  October 2022 Editorial The Slow Path to Therapeutic Adherence Francesco Ferrara, Livia Nava, Ugo Trama, Eduardo Nava, and Antonio Vitiello lEttErs to thE Editor Pharmacists' Contribution to COVID-19 Drug Related Expenditures Lauren M.

ABSTRACT Objectives To know the efficacy of different doses of dalbavancin in acute bacterial skin and skin-structure infections (ABSSSIs) and versus other antibiotics. Methods We performed a systematic review of dalbavancin efficacy for ABSSSIs. We selected 10 clinical trials from MEDLINE and Cochrane databases for qualitative review. Of these, five trials compared one or two doses of dalbavancin versus other antibiotics such as vancomycin or linezolid.